1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC

related topics
{product, candidate, development}
{stock, price, share}
{product, liability, claim}
{control, financial, internal}
We have limited experience in conducting clinical trials. We cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, therefore we cannot predict the timing of any future revenue from these product candidates. We may be unable to license gene transfer technologies that we may need to commercialize our ZFP TF technology. Our stock price is also influenced by public perception. If our competitors develop, acquire, or market technologies or products that are more effective than ours, this would reduce or eliminate our commercial opportunity. Our collaborators or strategic partners may decide to adopt alternative technologies or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products. Our common stock is relatively thinly traded, which means large transactions in our common stock may be difficult to conduct in a short time frame. If we do not successfully commercialize certain ZFP Therapeutic programs relating to diabetic neuropathy under our agreement with JDRF, JDRF may have the right to continue to advance the program and we may lose control of the intellectual property generated in the collaboration and development of the product and may only receive a portion of the revenue generated if commercialization by JDRF is successful Laws or public sentiment may limit the production of genetically modified agricultural products in the future, and these laws could reduce our partner s ability to sell these products.

Full 10-K form ▸
related documents
1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC
1020214--2/27/2006--CERUS_CORP
874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA
1017491--3/12/2008--NEXMED_INC
873303--3/16/2007--AVI_BIOPHARMA_INC
873303--3/16/2006--AVI_BIOPHARMA_INC
908259--3/14/2007--OXIGENE_INC
908259--3/14/2008--OXIGENE_INC
1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO
897075--3/14/2007--REPROS_THERAPEUTICS_INC.
1010086--3/13/2008--SIGA_TECHNOLOGIES_INC
1013238--3/31/2006--ARADIGM_CORP
817785--4/4/2007--IMMUNE_RESPONSE_CORP
858803--12/18/2006--AVANIR_PHARMACEUTICALS
1038133--3/30/2007--HESKA_CORP
1038133--3/31/2006--HESKA_CORP
1110803--3/6/2006--ILLUMINA_INC
1038133--3/16/2009--HESKA_CORP
1038133--3/3/2008--HESKA_CORP
1038133--2/22/2010--HESKA_CORP
874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA
1017491--3/26/2007--NEXMED_INC
1028358--3/31/2008--GENITOPE_CORP
1062822--3/12/2007--LEXICON_GENETICS_INC/TX
1001233--3/16/2006--SANGAMO_BIOSCIENCES_INC
71478--3/15/2006--LIPID_SCIENCES_INC/
12239--4/4/2008--SPHERIX_INC
810509--3/31/2008--NEOPROBE_CORP
907562--3/3/2006--DYAX_CORP
708717--10/15/2007--ALFACELL_CORP